SLC34A2 and tumor of uterus: Furthermore, we suggest that SLC34A2 upregulation—not only for ovary but also for myeloid, bowel, and uterine tumors—can be considered as a potential predictive marker for targeted therapy with monoclonal antibodies, including XMT-1536 and XMT-1592.